TITLE:

Direct synthesis of highly fused perimidines by copper(I)-catalyzed hydroamination of 2-ethynylbenzaldehydes

AUTHOR(S):

Tokimizu, Yusuke; Ohta, Yusuke; Chiba, Hiroaki; Oishi, Shinya; Fujii, Nobutaka; Ohno, Hiroaki

---

CITATION:

Tokimizu, Yusuke ...[et al]. Direct synthesis of highly fused perimidines by copper(I)-catalyzed hydroamination of 2-ethynylbenzaldehydes. *Tetrahedron* 2011, 67(29): 5168-5175

ISSUE DATE:

2011-07

URL:

<http://hdl.handle.net/2433/143596>

RIGHT:

© 2011 Elsevier Ltd.; この論文は出版社版ではありません。引用の際には出版社版をご確認ご利用ください。; This is not the published version. Please cite only the published version.

Graphical Abstract

Direct synthesis of highly fused perimidines by copper(I)-catalyzed hydroamination of 2- ethynylbenzaldehydes

Yusuke Tokimizu, Yusuke Ohta, Hiroaki Chiba, Shinya Oishi, Nobutaka Fujii,* Hiroaki Ohno*
Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan

Leave this area blank for abstract info.

Tetrahedron
journal homepage: www.elsevier.com

Direct synthesis of highly fused perimidines by copper(I)-catalyzed hydroamination of 2-ethynylbenzaldehydes

Yusuke Tokimizu, Yusuke Ohta, Hiroaki Chiba, Shinya Oishi, Nobutaka Fujii,* Hiroaki Ohno*

Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan

ARTICLE INFO

Article history:

Received

Received in revised form

Accepted

Available online

Keywords:

C-H arylation

polyarene

isoquinoline

perimidine

multi-component reaction

ABSTRACT

A novel synthesis of highly fused perimidine derivatives was achieved in two steps from 2-alkynylbenzaldehydes. Copper-catalyzed annulation of 2-[(2-bromophenyl)ethynyl]benzaldehydes with 1,8-diaminonaphthalene produced dihydroisoquinolino[2,1-*a*]perimidines bearing a 2-bromophenyl group. Subsequent palladium-catalyzed C-H arylation provided dibenzo[1,2:7,8]quinolizino[3,4,5,6-*kla*]perimidine derivatives in moderate to good yields.

2009 Elsevier Ltd. All rights reserved.

1. Introduction

Because of their charge mobility, highly-conjugated polycyclic compounds are important in practical applications for electronic materials, such as in dye lasers and electroluminescent materials.¹⁻⁵ Compounds with a cyclic amidine moiety, such as fused perimidine derivatives,⁶ are particularly useful because they have high π -stacking ability, electron affinity, and reduction potential, and can be used as core structures of biologically active compounds.⁷⁻⁹

We have an ongoing program directed toward fused isoquinoline synthesis based on four-component coupling and cyclization cascade (Scheme 1, eq 1).^{10,11} We postulated that a fused perimidine skeleton could be readily constructed by copper-catalyzed annulation of 2-ethynylbenzaldehyde **1** with 1,8-diaminonaphthalene **2** (eq 2). Use of 2-alkynylbenzaldehydes **1** bearing an aryl halide moiety (X = halogen) with palladium-catalyzed C-H arylation^{4,5,12-21} of the resulting perimidines **3** would provide facile access to a new class of highly fused perimidines **4**.

Scheme 1. Strategy for direct synthesis of highly fused perimidines

Scheme 2. Related reactions for synthesis of fused isoquinolines

Recently, several syntheses of isoquinoline-fused compounds using a diamine component have been reported (Scheme 2). Dyker *et al.* used 1,2-phenylenediamine for construction of a benzimidazo[2,1-*a*]isoquinoline skeleton from 2-

alkynylbenzaldehydes (eq 3).^{22,23} Yanada *et al.* reported palladium-catalyzed direct synthesis of benzimidazo[2,1-*a*]isoquinolines through one-pot Sonogashira coupling between 2-bromobenzaldehydes and an alkyne, followed by cyclization with 1,2-phenylenediamine (eq 4).²⁴ Sridhar *et al.* reported a gold-catalyzed reaction of 2-alkynylbenzaldehydes with aniline, which had another nucleophilic functionality such as pyrrole/indole/imidazole rings or amino/sulfonamide/hydroxy groups (eq 5).²⁵ However, annulation of 2-alkynylbenzaldehydes with a diamine component in which each of amino groups is located on a different benzene ring is unprecedented.²⁶ Here, we report a novel synthesis of highly fused perimidines **4** by copper-catalyzed coupling and cyclization of 2-alkynylbenzaldehydes **1** and 1,8-diaminonaphthalene **2**, followed by palladium-catalyzed C–H arylation (Scheme 1).

2. Results and discussion

The reaction conditions for the copper-catalyzed annulation using 2-[(2-bromophenyl)ethynyl]benzaldehyde **1a** and 1,8-diaminonaphthalene **2** were optimized (Table 1). When the aldehyde **1a** was treated with **2** in the presence of CuI (10 mol %) in DMF, the isoquinoline **6** was obtained as the oxidized form in 53% yield (entry 1). The use of dioxane as the solvent at 80 °C under an Ar or O₂ atmosphere was less effective, and produced the intermediate aminal **5** as the major product (56–67% yield) along with unoxidized isoquinoline **3a** (18–20% yield, entries 2 and 3). Although the reaction at higher temperature (120 °C) increased the yield of **3a** to 92% (entry 4), scaling up the reaction from 0.11 mmol to 1.1 mmol was unsuccessful (entry 5). The use of microwave irradiation solved this problem, and **3a** was produced in 91% yield on the 1.1 mmol scale (entry 6). Because microwave conditions in DMF led to an unsatisfactory result (entry 7), the conditions shown in entry 6 were used for further investigations.

Table 1. Optimization of reaction conditions for the coupling–cyclization^a

Reaction scheme showing the synthesis of products **3a**, **5**, **6**, and **7** from starting materials **1a** and **2** using CuI in a solvent.

Starting materials:

- 1a**: 2-[(2-bromophenyl)ethynyl]benzaldehyde
- 2**: 1,8-diaminonaphthalene

Products:

- 3a**: Naphtho[1,8-c:1',2'-d]quinoxaline derivative
- 5**: Naphtho[1,8-c:1',2'-d]quinoxaline derivative
- 6**: Naphtho[1,8-c:1',2'-d]quinoxaline derivative
- 7**: Naphtho[1,8-c:1',2'-d]quinoxaline derivative

entry	solvent	conditions	yield (%) ^c			
			3a	5	6	7
1	DMF	110 °C, 20 h	-	-	53	-
2	dioxane	80 °C, 10 h	20	67	-	-
3 ^d	dioxane	80 °C, 30 h	18	56	7	-
4	dioxane	reflux, 12 h	92	-	-	5
5 ^e	dioxane	reflux, 24 h	54	34	-	-
6 ^e	dioxane	MW ^b , 150 °C, 60 min	91	-	-	5
7	DMF	MW ^b , 140 °C, 60 min	56	-	7	31

^aUnless otherwise stated the reactions were conducted with **1a** (0.11 mmol) and **2** (1.2 equiv) in the presence of CuI (10 mol %) under Ar.

^bMW=microwave irradiation. ^cIsolated yields. ^dThe reaction was conducted under an O₂ atmosphere. ^eThe reactions were conducted on a 1.1 mmol scale.

The substrate scope of the copper-catalyzed annulation was then examined using substituted 2-alkynylbenzaldehydes **1b–h** (Table 2). These substrates were readily prepared by Sonogashira coupling of substituted 2-ethynylbenzaldehydes with 2-iodobromobenzene (see the experimental section). The substrates **1b–e**, bearing an electron-withdrawing (fluoro) or -donating (methyl or methoxy) substituent at the *para*- or *meta*-position to the formyl group, underwent the desired annulation under the standard reaction conditions. The corresponding fused perimidines **3b–e** were produced in good to excellent yields (71–97%, entries 1–4). Substitution with a fluoro group at the *ortho* position was also tolerated (entry 5). Influence of the benzene substitution at the alkyne terminus with a fluoro or methyl group was less important (entries 6 and 7). The substrates **1i** and **1j** without a bromo substituent also gave the desired products **3i** and **3j** in high yields (91%, entries 8 and 9).

Table 2. Coupling–cyclization of various 2-alkynylbenzaldehydes^a

entry	substrate	product	yield (%) ^b
1	1b/3b : R ¹ = F, R ² = H	3b–e	97
2	1c/3c : R ¹ = Me, R ² = H		97
3	1d/3d : R ¹ = H, R ² = F		89
4	1e/3e : R ¹ = H, R ² = OMe		71
5	1f	3f	89
6	1g/3g : R = F	3g, h	73
7	1h/3h : R = Me		91
8	1i/3i : R = H		91
9	1j/3j : R = Me		91

^aCompounds **1** (50 mg) and **2** (1.5 equiv) in dioxane were stirred for 1 h at 150 °C under microwave irradiation in the presence of CuI (10 mol %). ^bIsolated yields.

Table 4. Optimization of reaction conditions for palladium-catalyzed C-H arylation^a

entry	catalyst	ligand	solvent	base	temp.	time	yield (%) ^b
1	Pd(OAc) ₂	PPh ₃	dioxane	Cs ₂ CO ₃	reflux	5 h	40
2	Pd(OAc) ₂	P(<i>t</i> -Bu) ₃ ·HBF ₄	dioxane	Cs ₂ CO ₃	reflux	5 h	43
3	Pd(OAc) ₂	none	dioxane	Cs ₂ CO ₃	reflux	5 h	0
4	Pd(OAc) ₂	PPh ₃	dioxane	Cs ₂ CO ₃	MW, ^c 160 °C	15 min	27
5	Pd(OAc) ₂	PPh ₃	DMF	Cs ₂ CO ₃	130 °C	4 h	65
6	Pd(OAc) ₂	P(<i>t</i> -Bu) ₃ ·HBF ₄	DMF	Cs ₂ CO ₃	130 °C	6 h	56
7	Pd(PPh ₃) ₂ Cl ₂	PPh ₃	DMF	Cs ₂ CO ₃	130 °C	5 h	22
8	Pd(PPh ₃) ₄	PPh ₃	DMF	Cs ₂ CO ₃	130 °C	5 h	0
9	Pd(OAc) ₂	PPh ₃	toluene	Cs ₂ CO ₃	reflux	6 h	<60 ^d
10	Pd(OAc) ₂	PPh ₃	DMSO	Cs ₂ CO ₃	130 °C	6 h	<65 ^d
11	Pd(OAc) ₂	PPh ₃	propan-2-ol	Cs ₂ CO ₃	reflux	6 h	0
12	Pd(OAc) ₂	PPh ₃	EtOH	Cs ₂ CO ₃	reflux	4 h	0
13	Pd(OAc) ₂	PPh ₃	DMF	Na ₂ CO ₃	130 °C	4 h	39
14	Pd(OAc) ₂	PPh ₃	DMF	K ₂ CO ₃	130 °C	4 h	<57 ^d
15	Pd(OAc) ₂	PPh ₃	DMF	K ₃ PO ₄	130 °C	4 h	78
16	Pd(OAc) ₂	PPh ₃	DMF	KOAc	130 °C	4 h	<60 ^d

^aAll reactions were conducted using **3a** (0.06–0.07 mmol) in the presence of a palladium catalyst (10 mol %), ligand (25 mol %), and base (2 equiv).

^bIsolated yields. ^cMW=microwave irradiation. ^dContained inseparable impurities.

In order to expand the use of 1,8-diaminonaphthalene **2** as a precursor of other perimidine derivatives, we examined four-component annulation using 2-ethynylbenzaldehyde **8**, formaldehyde **9**, and secondary amine **10**. As shown in Table 3, the reaction with diisopropylamine, piperidine, and morpholine as the secondary amine component produced perimidines **11a–c** bearing an aminomethyl group (52–70% yield).

Table 3. Four-component synthesis of fused perimidines^a

entry	R ₂ NH	conditions ^b	product	yield (%) ^c
1	(<i>i</i> -Pr) ₂ NH	rt, 1 h	11a	52
2		rt, 6 h	11b	70
3		rt, 4 h	11c	61

^aAfter the three-component reaction of **8** (0.23 mmol), **9** (2 equiv), and **10** (2 equiv) in the presence of CuI (10 mol %) in dioxane, **2** (3 equiv) was added

and the reaction mixture was stirred for 1 h at 150 °C under microwave irradiation. ^bConditions for the reaction of **8** with **9** and **10**. ^cIsolated yields.

Next, palladium-catalyzed C–H arylation for the synthesis of highly fused perimidines was investigated. Isoquinoline **3a** was chosen as the model substrate for optimization of the cyclization conditions (Table 4). When isoquinoline **3a** was allowed to react with Pd(OAc)₂ (10 mol %) in the presence of PPh₃ (25 mol %) and Cs₂CO₃ (2 equiv) in dioxane, the desired heptacyclic perimidine **4a** as the oxidized form was obtained in 40% yield (entry 1). The use of P(*t*-Bu)₃·HBF₄ as a ligand slightly improved the yield (43%, entry 2). Reaction in the absence of phosphine as the ligand (entry 3) or under microwave irradiation at 160 °C (entry 4) was less effective. DMF was promising as the reaction solvent, and produced **4a** in 65% yield (entry 5). Among the palladium catalysts and phosphine ligands tested (entries 5–8), Pd(OAc)₂/PPh₃ was the most effective in DMF (entry 5). Other solvents (toluene, DMSO, propan-2-ol, and EtOH, entries 9–12) and bases (Na₂CO₃, K₂CO₃, K₃PO₄, and KOAc, entries 13–16) were also examined, and K₃PO₄ in DMF was the most effective (78% yield, entry 15).

Finally, a series of substrates with various substituent patterns were applied to the C–H arylation under the optimized conditions for **3a** (Table 5). All the substituted substrates **3b–h** afforded the desired products **4b–h** as the oxidized form (45–62% yield, entries 1–7). This result was independent of the substituents on the two benzene rings. The moderate yields were partly because crystallization was required for purification. Poor solubility of **4** in various nonpolar or polar solvents, including aromatic solvents, did not allow easy purification by column chromatography.

These results show that copper-catalyzed annulation of 2-alkynylbenzaldehydes **1** with 1,8-diaminonaphthalene **2**, and subsequent palladium-catalyzed arylation provides convenient access to highly fused perimidine derivatives.

Table 5. Synthesis of highly fused perimidines^a

entry	substrate/ product	R ¹	R ²	R ³	R ⁴	yield (%) ^b
1	3b/4b	F	H	H	H	45
2	3c/4c	Me	H	H	H	53
3	3d/4d	H	F	H	H	53
4	3e/4e	H	OMe	H	H	61
5	3f/4f	H	H	F	H	51
6	3g/4g	H	H	H	F	49
7	3h/4h	H	H	H	Me	62

^aAll reactions were conducted with **3** (30 mg) in the presence of K₃PO₄ (2 equiv), Pd(OAc)₂ (10 mol %), and PPh₃ (25 mol %) in DMF. ^b Isolated yields after recrystallization

3. Conclusions

Fused perimidine derivatives were synthesized by copper-catalyzed annulation of 2-alkynylbenzaldehydes **1** with 1,8-diaminonaphthalene **2**. The four-component approach was applied to this reaction to produce perimidine derivatives bearing an aminomethyl group. Palladium-catalyzed C-H arylation of perimidines bearing an aryl bromide moiety produced a new class of highly fused perimidine derivatives in moderate to good yields.

4. Experimental

4.1 General

¹H NMR spectra were recorded using a JEOL AL-500 spectrometer at 500 MHz frequency. Chemical shifts are reported in δ(ppm) relative to Me₄Si (in CDCl₃ or CD₃OD) as internal standard. ¹³C NMR spectra were recorded using a JEOL AL-500 and referenced to the residual CHCl₃ or MeOH signal. Melting points were measured by a hot stage melting points apparatus (uncorrected). For column chromatography, Wakogel C-300E was employed. Microwave reaction was conducted in a sealed glass vessel (capacity 10 mL) using CEM Discover microwave reactor with a run time of no more than 10 min at below 300 W. The commercially available compounds including **2**, **9**, **10a–c**, **13a–e**, and **14** were used without further purification.

The compounds **12a–e**¹⁰ and **12f**²⁷ were prepared according to the literature.

4.2. Preparation of Starting Materials

4.2.1. 2-[(2-Bromophenyl)ethynyl]benzaldehyde (1a). A mixture of 2-ethynylbenzaldehyde (**12a**) (1.00 g, 7.68 mmol), 1-bromo-2-iodobenzene (**13a**) (1.18 mL, 9.22 mmol), CuI (146 mg, 0.77 mmol), PdCl₂(PPh₃)₂ (107 mg, 0.15 mmol), and Et₃N (15 mL) in THF (15 mL) was stirred at 80 °C for 2 h under argon, and filtrated through a pad of celite. The filtrate was concentrated under reduced pressure and the residue was purified by column chromatography over silica gel with hexane–EtOAc (15:1) to give **1a** (1.81 g, 83%) as a colorless solid: mp 69 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.23 (ddd, *J* = 8.0, 8.0, 1.7 Hz, 1H, Ar), 7.33 (ddd, *J* = 8.0, 8.0, 1.1 Hz, 1H, Ar), 7.48 (dd, *J* = 8.0, 8.0 Hz, 1H, Ar), 7.58–7.62 (m, 2H, Ar), 7.64 (dd, *J* = 8.0, 1.1 Hz, 1H, Ar), 7.70 (d, *J* = 8.0 Hz, 1H, Ar), 7.97 (dd, *J* = 8.0, 1.1 Hz, 1H, Ar), 10.76 (s, 1H, CHO); ¹³C NMR (125 MHz, CDCl₃) δ 89.3, 94.6, 124.6, 125.8, 126.5, 127.2 (2C), 129.0, 130.1, 132.6, 133.4, 133.5, 133.8, 136.1, 191.9. *Anal.* Calcd. for C₁₅H₉BrO: C, 63.18; H, 3.18. Found: C, 63.20; H, 3.28.

4.2.2. 2-[(2-Bromophenyl)ethynyl]-4-fluorobenzaldehyde (1b). By a procedure identical with that described for the preparation of **1a**, 2-ethynyl-4-fluorobenzaldehyde (**12b**) (100 mg, 0.68 mmol) was converted to **1b** (169 mg, 83%) by the reaction with 1-bromo-2-iodobenzene (**13a**) (104 μL, 0.81 mmol), CuI (6.4 mg, 0.034 mmol), PdCl₂(PPh₃)₂ (23.7 mg, 0.034 mmol), and Et₃N (1.0 mL) in THF (1.0 mL) at 80 °C for 1.5 h: colorless solid: mp 109 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.17 (ddd, *J* = 8.0, 8.0, 2.1 Hz, 1H, Ar), 7.26 (ddd, *J* = 8.0, 8.0, 1.7 Hz, 1H, Ar), 7.33–7.38 (m, 2H, Ar), 7.60 (dd, *J* = 8.0, 1.7 Hz, 1H, Ar), 7.65 (d, *J* = 8.0 Hz, 1H, Ar), 8.00 (dd, *J* = 8.6, 5.7 Hz, 1H, Ar), 10.67 (s, 1H, CHO); ¹³C NMR (125 MHz, CDCl₃) δ 88.0 (d, *J* = 2.4 Hz), 95.6, 116.9 (d, *J* = 21.6 Hz), 119.8 (d, *J* = 22.8 Hz), 124.1, 125.9, 127.2, 128.9 (d, *J* = 10.8 Hz), 130.0 (d, *J* = 9.6 Hz), 130.5, 132.7, 132.9, 133.6, 165.6 (d, *J* = 256.7 Hz), 190.2. *Anal.* Calcd. for C₁₅H₈BrFO: C, 59.43; H, 2.66. Found: C, 59.49; H, 2.80.

4.2.3. 2-[(2-Bromophenyl)ethynyl]-4-methylbenzaldehyde (1c). By a procedure identical with that described for the preparation of **1a**, 2-ethynyl-4-methylbenzaldehyde (**12c**) (50 mg, 0.35 mmol) was converted to **1c** (78 mg, 75%) by the reaction with 1-bromo-2-iodobenzene (**13a**) (53.4 μL, 0.42 mmol), CuI (3.3 mg, 0.017 mmol), PdCl₂(PPh₃)₂ (12.2 mg, 0.017 mmol), and Et₃N (0.75 mL) in THF (0.75 mL) at 80 °C for 1 h: colorless solid: mp 79 °C; ¹H NMR (500 MHz, CDCl₃) δ 2.43 (s, 3H, CCH₃) 7.22 (ddd, *J* = 8.0, 8.0, 1.5 Hz, 1H, Ar), 7.27 (d, *J* = 8.0 Hz, 1H, Ar), 7.32 (ddd, *J* = 8.0, 8.0, 1.1 Hz, 1H, Ar), 7.50 (s, 1H, Ar), 7.58 (dd, *J* = 8.0, 1.7 Hz, 1H, Ar), 7.63 (dd, *J* = 8.0, 1.1 Hz, 1H, Ar), 7.86 (d, *J* = 8.0 Hz, 1H, Ar), 10.69 (s, 1H, CHO); ¹³C NMR (125 MHz, CDCl₃) δ 21.6, 89.5, 94.1, 124.7, 125.8, 126.4, 127.1, 127.2, 130.0 (2C), 132.6, 133.4, 133.7, 134.0, 144.8, 191.5. *Anal.* Calcd. for C₁₆H₁₁BrO: C, 64.24 H, 3.71. Found: C, 64.15; H, 3.82.

4.2.4. 2-[(2-Bromophenyl)ethynyl]-5-fluorobenzaldehyde (1d). By a procedure identical with that described for the preparation of **1a**, 2-ethynyl-5-fluorobenzaldehyde (**12d**) (100 mg, 0.68 mmol) was converted to **1d** (174 mg, 85%) by the reaction with 1-bromo-2-iodobenzene (**13a**) (104 μL, 0.81 mmol), CuI (6.4 mg, 0.034 mmol), PdCl₂(PPh₃)₂ (23.7 mg, 0.034 mmol), and Et₃N (1.0 mL) in THF (1.0 mL) at 80 °C for 1.5 h: colorless solid: mp 93 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.24 (ddd, *J* = 7.7, 7.7, 1.5 Hz, 1H, Ar), 7.28–7.34 (m, 2H, Ar), 7.58 (dd, *J* = 7.7, 1.4 Hz, 1H,

Ar), 7.62–7.64 (m, 2H, Ar), 7.69 (dd, $J = 8.6, 5.2$ Hz, 1H, Ar), 10.70 (d, $J = 3.4$ Hz, 1H, CHO); ^{13}C NMR (125 MHz, CDCl_3) δ 88.2, 94.4, 113.7 (d, $J = 22.8$ Hz), 121.3 (d, $J = 22.8$ Hz), 122.5 (d, $J = 3.6$ Hz), 124.4, 125.7, 127.2, 130.2, 132.6, 133.4, 135.4 (d, $J = 7.2$ Hz), 138.1 (d, $J = 7.2$ Hz), 162.6 (d, $J = 253.1$ Hz), 190.6. *Anal.* Calcd. for $\text{C}_{15}\text{H}_8\text{BrFO}$: C, 59.43; H, 2.66. Found: C, 59.60; H, 2.92.

4.2.5. 2-[(2-Bromophenyl)ethynyl]-5-methoxybenzaldehyde (1e). By a procedure identical with that described for the preparation of **1a**, 2-ethynyl-5-methoxybenzaldehyde (**12e**) (100 mg, 0.62 mmol) was converted to **1e** (167 mg, 85%) by the reaction with 1-bromo-2-iodobenzene (**13a**) (95.9 μL , 0.75 mmol), CuI (5.9 mg, 0.031 mmol), $\text{PdCl}_2(\text{PPh}_3)_2$ (21.9 mg, 0.031 mmol), and Et_3N (1.0 mL) in THF (1.0 mL) at 80 °C for 1 h: colorless solid: mp 102 °C; ^1H NMR (500 MHz, CDCl_3) δ 3.88 (s, 3H, CH_3), 7.14 (dd, $J = 8.6, 2.9$ Hz, 1H, Ar), 7.20 (ddd, $J = 7.7, 7.7, 1.3$ Hz, 1H, Ar), 7.31 (ddd, $J = 7.7, 7.7, 1.1$ Hz, 1H, Ar), 7.44 (d, $J = 2.9$ Hz, 1H, Ar), 7.56 (dd, $J = 8.0, 1.7$ Hz, 1H, Ar), 7.60–7.63 (m, 2H, Ar), 10.72 (s, 1H, CHO); ^{13}C NMR (125 MHz, CDCl_3) δ 55.6, 89.4, 93.3, 109.8, 119.1, 121.7, 124.9, 125.6, 127.1, 129.7, 132.5, 133.2, 134.7, 137.6, 160.1, 191.8. *Anal.* Calcd. for $\text{C}_{16}\text{H}_{11}\text{BrO}_2$: C, 60.98 H, 3.52. Found: C, 60.95; H, 3.41.

4.2.6. 2-[(2-Bromophenyl)ethynyl]-6-fluorobenzaldehyde (1f). By a procedure similar to that described for the preparation of **1a**, 2-fluoro-6-iodobenzaldehyde (**12f**) (50 mg, 0.20 mmol) was converted to **1f** (56 mg, 92%) by the reaction with 1-bromo-2-ethynylbenzene (**14**) (43.4 mg, 0.24 mmol), CuI (1.9 mg, 0.012 mmol), $\text{PdCl}_2(\text{PPh}_3)_2$ (7.0 mg, 0.012 mmol), and Et_3N (0.5 mL) in THF (0.5 mL) at 50 °C for 2 h: colorless solid: mp 74 °C; ^1H NMR (500 MHz, CDCl_3) δ 7.16 (ddd, $J = 7.7, 7.7, 3.6$ Hz, 1H, Ar), 7.24 (ddd, $J = 7.7, 7.7, 1.7$ Hz, 1H, Ar), 7.33 (ddd, $J = 7.7, 7.7, 1.1$ Hz, 1H, Ar), 7.50–7.57 (m, 2H, Ar), 7.61–7.64 (m, 2H, Ar), 10.70 (s, 1H, CHO); ^{13}C NMR (125 MHz, CDCl_3) δ 89.2 (d, $J = 4.8$ Hz), 95.2, 117.2 (d, $J = 21.6$ Hz), 124.4 (d, $J = 9.6$ Hz), 125.8, 127.0, 127.1 (d, $J = 25.2$ Hz), 129.7 (2C), 130.4, 132.6, 133.7, 134.8 (d, $J = 10.8$ Hz), 162.4 (d, $J = 262.7$ Hz), 188.5. *Anal.* Calcd. for $\text{C}_{15}\text{H}_8\text{BrFO}$: C, 59.43; H, 2.66. Found: C, 59.42; H, 2.93.

4.2.7. 2-[(2-Bromo-5-fluorophenyl)ethynyl]benzaldehyde (1g). By a procedure identical with that described for the preparation of **1a**, 2-ethynylbenzaldehyde (**12a**) (100 mg, 0.77 mmol) was converted to **1g** (177 mg, 91%) by the reaction with 1-bromo-4-fluoro-2-iodobenzene (**13b**) (83.7 μL , 0.64 mmol), CuI (6.1 mg, 0.032 mmol), $\text{PdCl}_2(\text{PPh}_3)_2$ (22.5 mg, 0.032 mmol), and Et_3N (1.5 mL) in THF (1.5 mL) at 50 °C for 2 h: colorless solid: mp 89–90 °C; ^1H NMR (500 MHz, CDCl_3) δ 6.96 (ddd, $J = 8.3, 8.3, 3.1$ Hz, 1H, Ar), 7.29 (dd, $J = 8.3, 2.9$ Hz, 1H, Ar), 7.49 (dd, $J = 7.4, 7.4$ Hz, 1H, Ar), 7.55–7.61 (m, 2H, Ar), 7.68 (d, $J = 7.4$ Hz, 1H, Ar), 7.96 (dd, $J = 7.4, 1.1$ Hz, 1H, Ar), 10.71 (s, 1H, CHO); ^{13}C NMR (125 MHz, CDCl_3) δ 90.2, 93.4 (d, $J = 3.6$ Hz), 117.7 (d, $J = 22.8$ Hz), 112.1 (d, $J = 24.0$ Hz), 120.3 (d, $J = 3.6$ Hz), 125.7, 126.0 (d, $J = 9.6$ Hz), 127.2, 129.3, 133.4, 133.7, 133.8 (d, $J = 9.6$ Hz), 136.2, 161.3 (d, $J = 248.3$ Hz), 191.4. *Anal.* Calcd. for $\text{C}_{15}\text{H}_8\text{BrFO}$: C, 59.43; H, 2.66. Found: C, 59.64; H, 2.95.

4.2.8. 2-[(2-Bromo-5-methylphenyl)ethynyl]benzaldehyde (1h). By a procedure identical with that described for the preparation of **1a**, 2-ethynylbenzaldehyde (**12a**) (200 mg, 1.54 mmol) was

converted to **1h** (331 mg, 72%) by the reaction with 1-bromo-2-iodo-4-methylbenzene (**13c**) (182 μL , 1.28 mmol), CuI (12.2 mg, 0.064 mmol), $\text{PdCl}_2(\text{PPh}_3)_2$ (44.9 mg, 0.064 mmol), and Et_3N (3.0 mL) in THF (3.0 mL) at 80 °C for 1 h: colorless solid: mp 93–94 °C; ^1H NMR (500 MHz, CDCl_3) δ 2.33 (s, 3H, CCH_3), 7.04 (dd, $J = 8.0, 2.0$ Hz, 1H, Ar), 7.42 (d, $J = 1.7$ Hz, 1H, Ar), 7.46–7.51 (m, 2H, Ar), 7.60 (ddd, $J = 7.4, 7.4, 1.1$ Hz, 1H, Ar), 7.69 (d, $J = 8.0$ Hz, 1H, Ar), 7.97 (dd, $J = 8.0, 1.1$ Hz, 1H, Ar), 10.76 (s, 1H, CHO); ^{13}C NMR (125 MHz, CDCl_3) δ 20.7, 88.9, 94.9, 122.4, 124.2, 126.6, 127.1, 128.9, 131.2, 132.3, 133.3, 133.7, 134.0, 136.1, 137.2, 192.0. *Anal.* Calcd. for $\text{C}_{16}\text{H}_{11}\text{BrO}$: C, 64.24 H, 3.71. Found: C, 64.44; H, 3.88.

4.2.9. 2-(Phenylethynyl)benzaldehyde (1i). By a procedure identical with that described for the preparation of **1a**, 2-ethynylbenzaldehyde (**12a**) (100 mg, 0.77 mmol) was converted to **1i** (111 mg, 70%) by the reaction with iodobenzene (**13d**) (103 μL , 0.92 mmol), CuI (7.3 mg, 0.038 mmol), $\text{PdCl}_2(\text{PPh}_3)_2$ (26.9 mg, 0.038 mmol), and Et_3N (1.0 mL) in THF (1.0 mL) at 80 °C for 1 h: yellow oil; ^1H NMR (500 MHz, CDCl_3) δ 7.37–7.39 (m, 3H, Ar), 7.44 (dd, $J = 7.7, 7.7$ Hz, 1H, Ar), 7.55–7.59 (m, 3H, Ar), 7.64 (d, $J = 7.4$ Hz, 1H, Ar), 7.95 (d, $J = 7.4$ Hz, 1H, Ar), 10.65 (s, 1H, CHO); ^{13}C NMR (125 MHz, CDCl_3) δ 84.9, 96.3, 122.3, 126.8, 127.2, 128.5 (2C), 128.6, 129.0, 131.7 (2C), 133.2, 133.7, 135.8, 191.6; HRMS (FAB) calcd for $\text{C}_{15}\text{H}_{11}\text{O}$ (MH^+): 207.0810; found: 207.0810.

4.2.10. 2-[(4-Methylphenyl)ethynyl]benzaldehyde (1j). By a procedure identical with that described for the preparation of **1a**, 2-ethynylbenzaldehyde (**12a**) (100 mg, 0.77 mmol) was converted to **1j** (120 mg, 71%) by the reaction with 1-iodo-2-methylbenzene (**13e**) (201 mg, 0.92 mmol), CuI (7.3 mg, 0.038 mmol), $\text{PdCl}_2(\text{PPh}_3)_2$ (26.9 mg, 0.038 mmol), and Et_3N (1.0 mL) in THF (1.0 mL) at 80 °C for 1 h: colorless solid: mp 48 °C; ^1H NMR (500 MHz, CDCl_3) δ 2.37 (s, 3H, CCH_3), 7.18 (d, $J = 8.0$ Hz, 2H, Ar), 7.40–7.46 (m, 3H, Ar), 7.56 (ddd, $J = 7.6, 7.6, 1.3$ Hz, 1H, Ar), 7.62 (d, $J = 6.9$ Hz, 1H, Ar), 7.93 (dd, $J = 7.6, 1.1$ Hz, 1H, Ar), 10.65 (s, 1H, CHO); ^{13}C NMR (125 MHz, CDCl_3) δ 21.5, 84.3, 96.6, 119.2, 127.1 (2C), 128.3, 129.2 (2C), 131.5 (2C), 133.1, 133.7, 135.7, 139.3, 191.7. *Anal.* Calcd. for $\text{C}_{16}\text{H}_{12}\text{O}$: C, 87.25; H, 5.49. Found: C, 87.11; H, 5.74.

4.3. Copper-catalyzed coupling–cyclization

4.3.1. General procedure: synthesis of 13-(2-Bromophenyl)-7,7a,12,13-dihydroisoquinolino[2,1-a]perimidine (3a) (Table 1, entry 6). A mixture of **1a** (50 mg, 0.18 mmol), 1,8-diaminonaphthalene (**2**) (41.5 mg, 0.26 mmol), and CuI (3.3 mg, 0.018 mmol) in dioxane (1.0 mL) was stirred for 60 min at 150 °C under microwave irradiation (300 W). The reaction mixture was concentrated under reduced pressure and purified by column chromatography over silica gel with hexane–EtOAc (15:1) to give **3a** (68 mg, 91%) as a pale yellow amorphous solid; ^1H NMR (500 MHz, CDCl_3) δ 4.49 (br s, 1H, NH), 5.68 (s, 1H, NCHN), 6.15 (s, 1H, C=CH), 6.36 (d, $J = 7.4$ Hz, 1H, Ar), 6.66 (dd, $J = 6.6, 2.0$ Hz, 1H, Ar), 6.96 (dd, $J = 8.0, 8.0$ Hz, 1H, Ar), 7.04–7.09 (m, 3H, Ar), 7.16 (d, $J = 7.4$ Hz, 1H, Ar), 7.21 (ddd, $J = 7.4, 7.4, 1.1$ Hz, 1H, Ar), 7.29–7.36 (m, 4H, Ar), 7.38–7.40 (m, 2H, Ar); ^{13}C NMR (125 MHz, CDCl_3) δ 69.3, 103.2, 107.6, 117.1, 118.5, 120.1, 123.0, 124.2, 124.4, 124.9, 125.8, 126.3, 126.4, 126.6, 126.7, 129.2 (2C), 131.9, 132.2, 132.3, 134.4, 137.8, 138.3, 142.1, 142.4; HRMS (FAB) calcd for $\text{C}_{25}\text{H}_{18}\text{BrN}_2$ (MH^+): 425.0653; found: 425.0649.

4.3.2. 13-(2-Bromophenyl)-10-fluoro-7,7a-dihydroisoquinolino[2,1-a]perimidine (3b) (Table 2, entry 1). By a procedure identical with that described for the preparation of **3a**, **1b** (50 mg, 0.17 mmol) was converted into **3b** (70 mg, 97%) by

the reaction with 1,8-diaminonaphthalene (**2**) (39.1 mg, 0.25 mmol) and CuI (3.1 mg, 0.017 mmol): yellow amorphous solid; ¹H NMR (500 MHz, CDCl₃) δ 4.45 (br s, 1H, NH), 5.57 (s, 1H, NCHN), 6.12 (s, 1H, C=CH), 6.32 (d, *J* = 7.4 Hz, 1H, Ar), 6.67 (dd, *J* = 6.9, 1.7 Hz, 1H, Ar), 6.82 (dd, *J* = 9.5, 2.6 Hz, 1H, Ar), 6.88 (ddd, *J* = 8.6, 8.6, 2.3 Hz, 1H, Ar), 6.93 (dd, *J* = 8.0, 8.0 Hz, 1H, Ar), 7.04-7.10 (m, 3H, Ar), 7.26-7.32 (m, 3H, Ar), 7.37-7.38 (m, 2H, Ar); ¹³C NMR (125 MHz, CDCl₃) δ 69.0, 102.2, 108.0, 110.4 (d, *J* = 21.6 Hz), 112.5 (d, *J* = 22.8 Hz), 117.5, 118.8, 120.3, 122.1 (d, *J* = 2.4 Hz), 123.5, 124.4, 124.9, 126.5, 126.8, 128.5 (d, *J* = 9.6 Hz), 129.5, 131.9, 132.4, 134.5, 134.6 (d, *J* = 9.6 Hz), 137.6, 138.0, 142.0, 143.7, 163.5 (d, *J* = 245.9 Hz); HRMS (FAB) calcd for C₂₅H₁₇BrFN₂ (MH⁺): 443.0560; found: 443.0558.

4.3.3. *13-(2-Bromophenyl)-10-methyl-7,7a-dihydroisoquinolino[2,1-a]perimidine (3c)* (Table 2, entry 2). By a procedure identical with that described for the preparation of **3a**, **1c** (50 mg, 0.17 mmol) was converted into **3c** (71 mg, 97%) by the reaction with 1,8-diaminonaphthalene (**2**) (39.6 mg, 0.25 mmol) and CuI (3.2 mg, 0.017 mmol): yellow amorphous solid; ¹H NMR (500 MHz, CDCl₃) δ 2.35 (s, 3H, CCH₃), 4.43 (br s, 1H, NH), 5.59 (s, 1H, NCHN), 6.10 (s, 1H, C=CH), 6.29 (d, *J* = 7.4 Hz, 1H, Ar), 6.64 (dd, *J* = 6.9, 1.1 Hz, 1H, Ar), 6.92 (dd, *J* = 7.7, 7.7 Hz, 1H, Ar), 6.95 (br s, 1H, Ar), 7.00-7.07 (m, 4H, Ar), 7.20 (d, *J* = 7.4 Hz, 1H, Ar), 7.24-7.30 (m, 2H, Ar), 7.34 (d, *J* = 8.0 Hz, 1H, Ar), 7.37 (d, *J* = 7.4 Hz, 1H, Ar); ¹³C NMR (125 MHz, CDCl₃) δ 21.3, 69.3, 103.2, 107.6, 117.2, 118.5, 120.2, 123.0, 123.8, 124.5, 124.8, 124.9, 126.4, 126.6, 126.7 (2C), 129.2, 132.0, 132.1, 132.4, 134.5, 138.0, 138.5, 139.0, 142.3, 142.4; HRMS (FAB) calcd for C₂₆H₂₀BrN₂ (MH⁺): 439.0810; found: 439.0805.

4.3.4. *13-(2-Bromophenyl)-9-fluoro-7,7a-dihydroisoquinolino[2,1-a]perimidine (3d)* (Table 2, entry 3). By a procedure identical with that described for the preparation of **3a**, **1d** (50 mg, 0.17 mmol) was converted into **3d** (65 mg, 89%) by the reaction with 1,8-diaminonaphthalene (**2**) (39.1 mg, 0.25 mmol) and CuI (3.1 mg, 0.017 mmol): yellow amorphous solid; ¹H NMR (500 MHz, CDCl₃) δ 4.50 (br s, 1H, NH), 5.67 (s, 1H, NCHN), 6.09 (s, 1H, C=CH), 6.31 (d, *J* = 7.4 Hz, 1H, Ar), 6.69 (dd, *J* = 6.6, 1.4 Hz, 1H, Ar), 6.93 (dd, *J* = 7.7, 7.7 Hz, 1H, Ar), 7.01-7.12 (m, 6H, Ar), 7.28-7.39 (m, 4H, Ar); ¹³C NMR (125 MHz, CDCl₃) δ 69.1 (d, *J* = 2.4 Hz), 103.1, 108.2, 113.6 (d, *J* = 22.8 Hz), 116.3 (d, *J* = 21.6 Hz), 117.1, 118.9, 120.1, 123.1, 124.4, 125.0, 126.0 (d, *J* = 8.4 Hz), 126.5, 126.8, 128.3 (d, *J* = 7.2 Hz), 128.7 (d, *J* = 2.4 Hz), 129.4, 131.9, 132.5, 134.4, 137.6, 138.1, 141.7, 141.9 (d, *J* = 2.4 Hz), 161.2 (d, *J* = 244.7 Hz); HRMS (FAB) calcd for C₂₅H₁₇BrFN₂ (MH⁺): 443.0560; found: 443.0552.

4.3.5. *13-(2-Bromophenyl)-9-methoxy-7,7a-dihydroisoquinolino[2,1-a]perimidine (3e)* (Table 2, entry 4). By a procedure identical with that described for the preparation of **3a**, **1e** (50 mg, 0.16 mmol) was converted into **3e** (51 mg, 71%) by the reaction with 1,8-diaminonaphthalene (**2**) (37.6 mg, 0.24 mmol) and CuI (3.0 mg, 0.016 mmol): yellow amorphous solid; ¹H NMR (500 MHz, CDCl₃) δ 3.84 (s, 3H, OCH₃), 4.54 (br s, 1H, NH), 5.68 (s, 1H, NCHN), 6.09 (s, 1H, C=CH), 6.30 (d, *J* = 7.4 Hz, 1H, Ar), 6.68 (dd, *J* = 6.9, 1.1 Hz, 1H, Ar), 6.89-6.91 (m, 2H, Ar), 6.93 (dd, *J* = 8.0, 8.0 Hz, 1H, Ar), 7.03-7.06 (m, 1H, Ar), 7.09-7.11 (m, 3H, Ar), 7.26-7.34 (m, 3H, Ar), 7.39 (d, *J* = 8.0 Hz, 1H, Ar); ¹³C NMR (125 MHz, CDCl₃) δ 55.5, 69.5, 103.9, 107.8, 112.2, 114.9, 116.8, 118.6, 120.0, 122.7, 124.6, 125.1, 125.5, 125.8, 126.4, 126.8, 128.3, 129.2, 132.1, 132.5, 134.5, 138.1, 138.5, 140.5, 142.0, 158.3; HRMS (FAB) calcd for C₂₆H₂₀BrN₂O (MH⁺): 455.0759; found: 455.0756.

4.3.6.

13-(2-Bromophenyl)-8-fluoro-7,7a-dihydroisoquinolino[2,1-a]perimidine (3f) (Table 2, entry 5). By a procedure identical with that described for the preparation of **3a**, **1f** (50 mg, 0.17 mmol) was converted into **3f** (65 mg, 89%) by the reaction with 1,8-diaminonaphthalene (**2**) (39.1 mg, 0.25 mmol) and CuI (3.1 mg, 0.017 mmol): yellow amorphous solid; ¹H NMR (500 MHz, CDCl₃) δ 4.53 (br s, 1H, NH), 5.62 (d, *J* = 1.7 Hz, 1H, NCHN), 6.33 (br s, 1H, Ar), 6.46 (s, 1H, C=CH), 6.70 (dd, *J* = 6.9, 1.7 Hz, 1H, Ar), 6.89-6.95 (m, 3H, Ar), 7.05-7.08 (m, 2H, Ar), 7.27-7.33 (m, 3H, Ar), 7.38-7.40 (m, 2H, Ar); ¹³C NMR (125 MHz, CDCl₃) δ 64.3, 102.2, 107.8, 112.2 (d, *J* = 21.6 Hz), 113.0 (d, *J* = 15.6 Hz), 117.6, 118.7, 120.0 (d, *J* = 2.4 Hz), 123.6, 124.4, 124.8, 126.5, 126.8, 129.4, 130.6 (d, *J* = 9.6 Hz), 131.8, 132.4, 134.4, 134.6 (d, *J* = 4.8 Hz), 137.5, 138.1, 140.9, 142.6, 143.5, 159.9 (d, *J* = 245.9 Hz); HRMS (FAB) calcd for C₂₅H₁₇BrFN₂ (MH⁺): 443.0560; found: 443.0555.

4.3.7.

13-(2-Bromo-5-fluorophenyl)-7,7a-dihydroisoquinolino[2,1-a]perimidine (3g) (Table 2, entry 6). By a procedure identical with that described for the preparation of **3a**, **1g** (50 mg, 0.17 mmol) was converted into **3g** (53 mg, 73%) by the reaction with 1,8-diaminonaphthalene (**2**) (39.1 mg, 0.25 mmol) and CuI (3.1 mg, 0.017 mmol): pale yellow amorphous solid; ¹H NMR (500 MHz, CDCl₃) δ 4.48 (br s, 1H, NH), 5.64 (s, 1H, NCHN), 6.12 (s, 1H, C=CH), 6.33 (d, *J* = 7.4 Hz, 1H, Ar), 6.66 (dd, *J* = 6.3, 1.7 Hz, 1H, Ar), 6.79 (ddd, *J* = 8.4, 8.4, 3.2 Hz, 1H, Ar), 6.89 (br s, 1H, Ar), 6.97 (dd, *J* = 7.7, 7.7 Hz, 1H, Ar), 7.13 (d, *J* = 7.4 Hz, 1H, Ar), 7.21 (ddd, *J* = 7.4, 7.4, 1.1 Hz, 1H, Ar), 7.27-7.34 (m, 5H, Ar), 7.38 (d, *J* = 7.4 Hz, 1H, Ar); ¹³C NMR (125 MHz, CDCl₃) δ 69.3, 103.5, 107.9, 116.6 (d, *J* = 22.8 Hz), 116.9, 118.7, 118.9 (d, *J* = 3.6 Hz), 119.0 (d, *J* = 22.8 Hz), 120.2, 123.3, 124.5, 124.9, 126.2, 126.5, 126.6, 126.7, 129.3, 132.0, 133.7 (d, *J* = 7.2 Hz), 134.5, 137.6, 140.1 (d, *J* = 8.4 Hz), 141.5, 142.0, 161.3 (d, *J* = 248.3 Hz); HRMS (FAB) calcd for C₂₅H₁₇BrFN₂ (MH⁺): 443.0560; found: 443.0560.

4.3.8.

13-(2-Bromo-5-methylphenyl)-7,7a-dihydroisoquinolino[2,1-a]perimidine (3h) (Table 2, entry 7). By a procedure identical with that described for the preparation of **3a**, **1h** (50 mg, 0.17 mmol) was converted into **3h** (67 mg, 91%) by the reaction with 1,8-diaminonaphthalene (**2**) (39.6 mg, 0.25 mmol) and CuI (3.2 mg, 0.017 mmol): yellow amorphous solid; ¹H NMR (500 MHz, CDCl₃) δ 2.16 (s, 3H, CCH₃), 4.52 (br s, 1H, NH), 5.64 (s, 1H, NCHN), 6.15 (s, 1H, C=CH), 6.31 (d, *J* = 7.4 Hz, 1H, Ar), 6.67 (dd, *J* = 6.6, 1.4 Hz, 1H, Ar), 6.87 (dd, *J* = 8.3, 2.0 Hz, 1H, Ar), 6.95 (dd, *J* = 8.0, 8.0 Hz, 1H, Ar), 6.98 (br s, 1H, Ar), 7.13 (d, *J* = 7.4 Hz, 1H, Ar), 7.18-7.22 (m, 2H, Ar), 7.26-7.33 (m, 4H, Ar), 7.36 (d, *J* = 8.0 Hz, 1H, Ar); ¹³C NMR (125 MHz, CDCl₃) δ 20.7, 69.4, 103.2, 107.8, 117.0, 118.6, 120.3, 121.0, 123.0, 124.3, 124.9, 125.8, 126.4, 126.5, 126.6, 129.3, 130.2, 132.1, 132.4, 132.6, 134.5, 136.7, 137.9, 138.0, 142.2, 142.7; HRMS (FAB) calcd for C₂₆H₂₀BrN₂ (MH⁺): 439.0810; found: 439.0807.

4.3.9. *13-Phenyl-7,7a-dihydroisoquinolino[2,1-a]perimidine (3i)* (Table 2, entry 8). By a procedure identical with that described for the preparation of **3a**, **1i** (50 mg, 0.24 mmol) was converted into **3i** (76 mg, 91%) by the reaction with 1,8-diaminonaphthalene (**2**) (57.5 mg, 0.36 mmol) and CuI (4.6 mg, 0.024 mmol): pale yellow amorphous solid; ¹H NMR (500 MHz, CDCl₃) δ 4.94 (br s, 1H, NH), 5.80 (s, 1H, NCHN), 6.14 (d, *J* = 7.4 Hz, 1H, Ar), 6.55 (br s, 1H, C=CH), 6.77 (d, *J* = 7.4 Hz, 1H, Ar), 6.92 (dd, *J* = 7.7, 7.7 Hz, 1H, Ar), 7.14 (dd, *J* = 7.4, 7.4 Hz, 1H, Ar), 7.18-7.22 (m, 4H, Ar), 7.27-7.32 (m, 5H, Ar), 7.49 (m, 2H, Ar); ¹³C NMR (125 MHz, CDCl₃) δ 68.3, 107.5, 113.2, 116.7, 118.2, 120.3 (2C), 124.4 (2C), 125.1, 125.9, 126.6, 126.9, 127.1 (2C), 128.3 (2C), 128.4 (2C), 133.5, 134.3, 136.6, 138.1, 139.7,

144.5; HRMS (FAB) calcd for $C_{25}H_{19}N_2$ (MH^+): 347.1548; found: 347.1547.

4.3.10. *13-(p-Tolyl)-7,7a-dihydroisoquinolino[2,1-a]perimidine (3j)* (Table 2, entry 9). By a procedure identical with that described for the preparation of **3a**, **1j** (50 mg, 0.23 mmol) was converted into **3j** (75 mg, 91%) by the reaction with 1,8-diaminonaphthalene (**2**) (53.8 mg, 0.34 mmol) and CuI (4.3 mg, 0.023 mmol): yellow amorphous solid; ^1H NMR (500 MHz, $CDCl_3$) δ 2.33 (s, 3H, CCH_3), 4.97 (br s, 1H, NH), 5.76 (s, 1H, NCHN), 6.15 (d, $J = 7.4$ Hz, 1H, Ar), 6.58 (br s, 1H, C=CH), 6.77 (d, $J = 7.4$ Hz, 1H, Ar), 6.93 (dd, $J = 8.0, 8.0$ Hz, 1H, Ar), 7.08-7.14 (m, 3H, Ar), 7.17-7.21 (m, 4H, Ar), 7.27 (d, $J = 7.4$ Hz, 1H, Ar), 7.30 (dd, $J = 7.7, 7.7$ Hz, 1H, Ar), 7.43 (m, 2H, Ar); ^{13}C NMR (125 MHz, $CDCl_3$) δ 21.3, 68.2, 107.5, 112.8, 116.4, 118.1, 120.0 (2C), 124.2 (2C), 125.0, 126.0, 126.6, 126.8, 126.9 (2C), 128.2, 129.2 (2C), 132.3, 133.8, 134.2, 138.2, 138.3, 139.6, 144.7; HRMS (FAB) calcd for $C_{26}H_{21}N_2$ (MH^+): 361.1705; found: 361.1705.

4.3.11. *General procedure for four-component coupling-cyclization: synthesis of N-[(7,7a-dihydroisoquinolino[2,1-a]perimidin-13-yl)methyl]-N-isopropylpropan-2-amine (11a)* (Table 3, entry 1). A mixture of 2-ethynylbenzaldehyde (**8**) (30 mg, 0.23 mmol), paraformaldehyde (**9**) (13.8 mg, 0.46 mmol), diisopropylamine (**10a**) (65.3 μ L, 0.46 mmol), and CuI (4.4 mg, 0.023 mmol) in dioxane (1.0 mL) was stirred at rt for 1 h. After the Mannich-type reaction was completed (monitored by TLC), 1,8-diaminonaphthalene (**2**) (109 mg, 0.69 mmol) was added, and the mixture was stirred for additional 60 min at 150 $^{\circ}C$ under microwave irradiation (300 W). The mixture was concentrated under reduced pressure and purified by column chromatography over silica gel with hexane-EtOAc (25:1) to give **11a** (46 mg, 52% yield) as a pale yellow amorphous solid; ^1H NMR (500 MHz, $CDCl_3$) δ 0.68 (d, $J = 6.3$ Hz, 6H, $2 \times CCH_3$), 0.87 (d, $J = 6.3$ Hz, 6H, $2 \times CCH_3$), 2.88-2.97 (m, 3H, $2 \times N-CH$ and $N-CHH$), 3.37 (d, $J = 16.0$ Hz, 1H, $N-CHH$), 4.25 (br s, 1H, NH), 5.87 (s, 1H, NCHN), 6.10 (s, 1H, C=CH), 6.58 (dd, $J = 5.7, 2.3$ Hz, 1H, Ar), 7.09-7.13 (m, 3H, Ar), 7.21 (d, $J = 6.9$ Hz, 1H, Ar), 7.27-7.31 (m, 3H, Ar), 7.36 (dd, $J = 7.7, 7.7$ Hz, 1H, Ar), 7.57 (d, $J = 8.6$ Hz, 1H, Ar); ^{13}C NMR (125 MHz, $CDCl_3$) δ 20.4 (2C), 20.5 (2C), 47.5, 48.0 (2C), 70.1, 101.4, 107.3, 118.0, 118.1, 120.0, 123.7, 124.0, 124.9, 125.5, 126.4 (2C), 126.6, 129.2, 133.2, 134.7, 138.6, 142.8, 144.0; HRMS (FAB) calcd for $C_{26}H_{30}N_3$ (MH^+): 384.2440; found: 384.2438.

4.3.12. *13-(Piperidin-1-ylmethyl)-7,7a-dihydroisoquinolino[2,1-a]perimidine (11b)* (Table 3, entry 2). By a procedure identical with that described for the preparation of **11a**, **8** (30 mg, 0.23 mmol) was converted into **11b** (60 mg, 70%) by the reaction with piperidine (**10b**) (45.6 μ L, 0.46 mmol): pale yellow amorphous solid; ^1H NMR (500 MHz, $CDCl_3$) δ 1.00-1.04 (m, 4H, $2 \times CH_2$), 1.13 (br t, $J = 5.4$ Hz, 2H, CH_2), 2.03-2.16 (m, 4H, $2 \times NCH_2$), 2.73 (d, $J = 13.2$ Hz, 1H, NCHH), 3.10 (d, $J = 13.2$ Hz, 1H, N-CHH), 4.17 (br s, 1H, NH), 5.72 (s, 1H, NCHN), 5.88 (s, 1H, C=CH), 6.54 (dd, $J = 6.9, 1.1$ Hz, 1H, Ar), 7.09 (d, $J = 7.4$ Hz, 1H, Ar), 7.13 (ddd, $J = 7.4, 7.4, 1.1$ Hz, 1H, Ar), 7.19 (d, $J = 6.9$ Hz, 1H, Ar), 7.22-7.35 (m, 5H, Ar), 7.55 (dd, $J = 7.7, 2.0$ Hz, 1H, Ar); ^{13}C NMR (125 MHz, $CDCl_3$) δ 24.3, 25.7 (2C), 53.5 (2C), 60.8, 69.7, 103.1, 107.1, 117.6, 118.1, 120.5, 123.7, 124.0, 125.4 (2C), 126.3, 126.5, 126.7, 129.2, 132.6, 134.6, 139.5, 141.2, 142.6; HRMS (FAB) calcd for $C_{25}H_{26}N_3$ (MH^+): 368.2127; found: 368.2130.

4.3.13. *4-[(7,7a-Dihydroisoquinolino[2,1-a]perimidin-13-yl)methyl]morpholine (11c)* (Table 3, entry 3). By a procedure identical with that described for the preparation of **11a**, **8** (30 mg, 0.23 mmol) was converted into **11c** (52 mg, 61%) by the reaction

with morpholine (**10c**) (40.2 μ L, 0.46 mmol): yellow amorphous solid; ^1H NMR (500 MHz, $CDCl_3$) δ 1.95 (br m, 2H, $2 \times N-CHH$), 2.25 (br m, 2H, $2 \times N-CHH$), 2.72 (d, $J = 13.2$ Hz, 1H, $N-CHH$), 2.93-3.00 (m, 4H, $2 \times OCH_2$), 3.33 (d, $J = 13.2$ Hz, 1H, $N-CHH$), 4.19 (br s, 1H, NH), 5.72 (s, 1H, NCHN), 5.90 (s, 1H, C=CH), 6.56 (d, $J = 6.9$ Hz, 1H, Ar), 7.11 (d, $J = 7.4$ Hz, 1H, Ar), 7.17 (dd, $J = 7.2, 7.2$ Hz, 1H, Ar), 7.21-7.35 (m, 6H, Ar), 7.57 (d, $J = 8.6$ Hz, 1H, Ar); ^{13}C NMR (125 MHz, $CDCl_3$) δ 52.3 (2C), 60.2, 66.6 (2C), 69.7, 104.0, 107.1, 117.1, 118.1, 120.8, 123.9, 124.2, 125.3, 125.7, 126.6 (2C), 127.0, 129.4, 132.4, 134.7, 139.8, 140.4, 142.5; HRMS (FAB) calcd for $C_{24}H_{24}N_3O$ (MH^+): 370.1919; found: 370.1921.

4.4. Palladium-catalyzed C-H arylation

4.4.1. *General procedure: synthesis of dibenzo[1,2:7,8]quinolizino[3,4,5,6-*kla*]perimidine (4a) hydrochloride* (Table 4, entry 15). A mixture of **3a** (50 mg, 0.12 mmol), $Pd(OAc)_2$ (2.7 mg, 0.012 mmol), PPh_3 (7.7 mg, 0.029 mmol), and K_3PO_4 (50.2 mg, 0.24 mmol) in DMF (1.5 mL) was stirred for 4 h at 130 $^{\circ}C$. The reaction mixture was concentrated under reduced pressure and purified by column chromatography over silica gel with toluene-EtOAc (200:1) to give **4a** (32 mg, 78%) as a red solid. When the C-H arylation products were poorly soluble in various organic solvents, their hydrochlorides were prepared as follows: the solid was dissolved in $CHCl_3$, and 4N solution of HCl in dioxane was added to the mixture. The precipitates were collected by filtration to give **4a**·HCl as a brown solid: mp 124–126 $^{\circ}C$; ^1H NMR (500 MHz, CD_3OD , 60 $^{\circ}C$) δ 6.58 (d, $J = 7.4$ Hz, 1H, Ar), 6.69 (d, $J = 6.9$ Hz, 1H, Ar), 6.74-6.79 (m, 2H, Ar), 6.93 (br s, 2H, Ar), 7.19 (d, $J = 8.0$ Hz, 1H, Ar), 7.25 (br s, 1H, Ar), 7.44-7.50 (m, 3H, Ar), 7.58 (br s, 1H, Ar), 7.67 (dd, $J = 6.6, 6.6$ Hz, 1H, Ar), 8.18 (d, $J = 8.0$ Hz, 1H, Ar); ^{13}C NMR (125 MHz, CD_3OD , 60 $^{\circ}C$) δ 110.9, 111.2, 116.1, 116.9, 119.7, 122.5, 123.4, 123.8, 124.7, 125.6, 125.7, 126.8, 128.1, 128.4, 129.2, 131.0, 131.2, 131.3, 133.0 (2C), 134.8, 134.9, 137.1, 137.2, 148.9; HRMS (FAB) calcd for $C_{25}H_{15}N_2$ (MH^+): 343.1235; found: 343.1233.

4.4.2. *12-Fluorodibenzo[1,2:7,8]quinolizino[3,4,5,6-*kla*]perimidine (4b)* (Table 5, entry 1). A mixture of **3b** (30 mg, 0.068 mmol), $Pd(OAc)_2$ (1.5 mg, 0.007 mmol), PPh_3 (4.4 mg, 0.017 mmol), and K_3PO_4 (28.7 mg, 0.14 mmol) in DMF (1.0 mL) was stirred for 4 h at 130 $^{\circ}C$. The reaction mixture was concentrated under reduced pressure and purified by column chromatography over silica gel with toluene-EtOAc (200:1) to give **4b** including some impurities. Recrystallization from pyridine gave pure **4b** (11 mg, 45%) as red crystals: mp 298–300 $^{\circ}C$; ^1H NMR (500 MHz, $CDCl_3$, 60 $^{\circ}C$) δ 6.57 (s, 1H, Ar), 6.63 (d, $J = 7.4$ Hz, 1H, Ar), 6.79 (dd, $J = 4.6, 4.6$ Hz, 1H, Ar), 6.90 (dd, $J = 8.3, 8.3$ Hz, 2H, Ar), 7.09-7.14 (m, 2H, Ar), 7.22-7.28 (m, 1H, Ar), 7.36 (dd, $J = 7.4, 7.4$ Hz, 1H, Ar), 7.56 (d, $J = 9.2$ Hz, 1H, Ar), 7.70 (d, $J = 8.0$ Hz, 1H, Ar), 7.75 (d, $J = 8.0$ Hz, 1H, Ar), 8.33 (dd, $J = 8.9, 6.0$ Hz, 1H, Ar); ^{13}C NMR assignment was difficult due to the poor solubility of **4b** as well as C-F couplings; HRMS (FAB) calcd for $C_{25}H_{14}FN_2$ (MH^+): 361.1141; found: 361.1143.

4.4.3. *12-Methyldibenzo[1,2:7,8]quinolizino[3,4,5,6-*kla*]perimidine (4c) hydrochloride* (Table 5, entry 2). By a procedure identical with that described for the preparation of **4b**, **3c** (30 mg, 0.068 mmol) was converted into **4c** (13 mg, 53%) by the reaction with $Pd(OAc)_2$ (1.5 mg, 0.007 mmol), PPh_3 (4.5 mg, 0.017 mmol), and K_3PO_4 (29.0 mg, 0.14 mmol) as red crystals. The crystals were dissolved in $CHCl_3$, and 4N solution of HCl in dioxane was added to the mixture. After hexane was added to the mixture, the precipitates were collected by filtration to give **4c**·HCl as a brown solid: mp 128–130 $^{\circ}C$; ^1H NMR (500 MHz,

CD₃OD) δ 2.39 (s, 3H, CCH₃), 6.61 (d, J = 5.7 Hz, 1H, Ar), 6.73 (d, J = 8.0 Hz, 1H, Ar), 6.88 (dd, J = 7.4, 7.4 Hz, 1H, Ar), 6.96 (d, J = 9.2 Hz, 1H, Ar), 7.00 (dd, J = 7.4, 7.4 Hz, 1H, Ar), 7.07 (dd, J = 7.4, 7.4 Hz, 1H, Ar), 7.17 (s, 1H, Ar), 7.29 (d, J = 8.0 Hz, 1H, Ar), 7.39 (d, J = 8.6 Hz, 1H, Ar), 7.43-7.45 (m, 2H, Ar), 7.60 (d, J = 7.4 Hz, 1H, Ar), 7.97 (d, J = 8.0 Hz, 1H, Ar); ¹³C NMR (125 MHz, CD₃OD) δ 22.1, 110.3, 110.9, 113.9, 116.9, 119.5, 122.6, 123.5, 123.7, 124.7, 125.4, 125.5, 126.9, 128.0, 128.3, 128.4, 130.9, 131.2, 132.9, 133.0, 133.1, 134.9, 135.0, 137.1, 148.5, 149.3; HRMS (FAB) calcd for C₂₆H₁₇N₂ (MH⁺): 357.1392; found: 357.1390.

4.4.4. *13-Fluorodibenzo[1,2:7,8]quinolizino[3,4,5,6-*kla*]perimidine (4d) (Table 5, entry 3).* By a procedure identical with that described for the preparation of **4b**, **3d** (30 mg, 0.068 mmol) was converted into **4d** (13 mg, 53%) by the reaction with Pd(OAc)₂ (1.5 mg, 0.007 mmol), PPh₃ (4.4 mg, 0.017 mmol), and K₃PO₄ (28.7 mg, 0.14 mmol) as red crystals: mp 283–285 °C; ¹H NMR (500 MHz, CDCl₃, 60 °C) δ 6.60-6.62 (m, 2H, Ar), 6.87 (d, J = 8.0 Hz, 1H, Ar), 7.06-7.16 (m, 4H, Ar), 7.20 (dd, J = 8.3, 8.3 Hz, 1H, Ar), 7.32 (dd, J = 7.7, 7.7 Hz, 1H, Ar), 7.52 (d, J = 9.2 Hz, 1H, Ar), 7.66 (dd, J = 8.0, 2.9 Hz, 1H, Ar), 7.71 (d, J = 8.0 Hz, 1H, Ar), 7.98 (dd, J = 10.3, 2.3 Hz, 1H, Ar); ¹³C NMR assignment was difficult due to the poor solubility of **4d** as well as C–F couplings; HRMS (FAB) calcd for C₂₅H₁₄FN₂ (MH⁺): 361.1141; found: 361.1140.

4.4.5. *13-Methoxydibenzo[1,2:7,8]quinolizino[3,4,5,6-*kla*]perimidine (4e) hydrochloride (Table 5, entry 4).* By a procedure identical with that described for the preparation of **4b**, **3e** (30 mg, 0.066 mmol) was converted into **4e** (15 mg, 61%) by the reaction with Pd(OAc)₂ (1.5 mg, 0.007 mmol), PPh₃ (4.3 mg, 0.017 mmol), and K₃PO₄ (28.0 mg, 0.13 mmol) as red crystals. The crystals were dissolved in CHCl₃, and 4N solution of HCl in dioxane was added to the mixture. Hexane was added to the mixture and the precipitates were collected by filtration to give **4e**·HCl as a brown solid: mp 140–141 °C; ¹H NMR (500 MHz, CD₃OD) δ 4.03 (s, 3H, OCH₃), 6.92 (d, J = 6.9 Hz, 1H, Ar), 7.02 (d, J = 8.0 Hz, 1H, Ar), 7.09 (dd, J = 7.4, 7.4 Hz, 1H, Ar), 7.34 (m, 2H, Ar), 7.40 (dd, J = 7.4, 7.4 Hz, 1H, Ar), 7.47 (d, J = 9.2 Hz, 1H, Ar), 7.67 (d, J = 9.2 Hz, 1H, Ar), 7.71 (s, 1H, Ar), 7.79 (d, J = 9.2 Hz, 1H, Ar), 7.85 (m, 1H, Ar), 7.91 (s, 1H, Ar), 7.96 (d, J = 7.4 Hz, 1H, Ar); ¹³C NMR (125 MHz, CD₃OD) δ 57.3, 104.5, 110.5, 110.9, 117.9, 118.1, 120.8, 123.1, 123.6, 123.9, 125.7, 126.1, 127.7, 127.8, 128.1, 129.1, 131.0, 131.3, 132.7, 132.8, 132.9, 134.1, 134.4, 135.7, 148.7, 162.6; HRMS (FAB) calcd for C₂₆H₁₇N₂O (MH⁺): 373.1341; found: 373.1341.

4.4.6. *14-Fluorodibenzo[1,2:7,8]quinolizino[3,4,5,6-*kla*]perimidine (4f) hydrochloride (Table 5, entry 5).* By a procedure identical with that described for the preparation of **4b**, **3f** (30 mg, 0.068 mmol) was converted into **4f** (13 mg, 51%) by the reaction with Pd(OAc)₂ (1.5 mg, 0.007 mmol), PPh₃ (4.4 mg, 0.017 mmol), and K₃PO₄ (28.7 mg, 0.14 mmol) as red crystals. The crystals were dissolved in CHCl₃, and 4N solution of HCl in dioxane was added to the mixture. After hexane was added to the mixture, the precipitates were collected by filtration to give **4f**·HCl as a brown solid: mp 130–131 °C; ¹H NMR (500 MHz, CD₃OD, 50 °C) δ 6.75 (d, J = 7.4 Hz, 1H, Ar), 7.07 (d, J = 8.0 Hz, 1H, Ar), 7.16 (dd, J = 8.0, 8.0 Hz, 1H, Ar), 7.31-7.34 (m, 2H, Ar), 7.38 (dd, J = 7.4, 7.4 Hz, 1H, Ar), 7.44 (dd, J = 14.0, 7.7 Hz, 1H, Ar), 7.61 (d, J = 8.0 Hz, 1H, Ar), 7.81 (d, J = 9.2 Hz, 1H, Ar), 7.86-7.89 (m, 2H, Ar), 8.00 (s, 1H, Ar), 8.07 (d, J = 8.0 Hz, 1H, Ar); ¹³C NMR (125 MHz, CD₃OD, 50 °C) δ 107.3 (d, J = 7.2 Hz), 110.5, 111.7, 116.7 (d, J = 22.8 Hz), 117.6, 120.6, 123.2, 123.9, 124.4, 125.2, 125.7 (d, J = 3.6 Hz), 126.4, 128.1, 128.3, 129.5, 131.2, 131.5, 133.1, 133.6, 135.5, 136.7, 138.6 (d, J = 10.8 Hz),

139.7 (d, J = 8.4 Hz), 148.7, 160.8 (d, J = 257.9 Hz); HRMS (FAB) calcd for C₂₅H₁₄FN₂ (MH⁺): 361.1141; found: 361.1143.

4.4.7. *8-Fluorodibenzo[1,2:7,8]quinolizino[3,4,5,6-*kla*]perimidine (4g) hydrochloride (Table 5, entry 6).* By a procedure identical with that described for the preparation of **4b**, **3g** (30 mg, 0.068 mmol) was converted into **4g** (12 mg, 49%) by the reaction with Pd(OAc)₂ (1.5 mg, 0.007 mmol), PPh₃ (4.4 mg, 0.017 mmol), and K₃PO₄ (28.7 mg, 0.14 mmol) as red crystals. The crystals were dissolved in CHCl₃, and 4N solution of HCl in dioxane was added to the mixture. After hexane was added to the mixture, the precipitates were collected by filtration to give **4g**·HCl as a brown solid: mp 280–281 °C; ¹H NMR (500 MHz, CD₃OD, 60 °C) δ 6.75 (d, J = 6.9 Hz, 1H, Ar), 6.83 (d, J = 8.0 Hz, 1H, Ar), 6.93-6.98 (m, 2H, Ar), 7.05 (d, J = 8.6 Hz, 1H, Ar), 7.46 (d, J = 9.2 Hz, 1H, Ar), 7.55-7.58 (m, 3H, Ar), 7.64-7.67 (m, 2H, Ar), 7.75 (dd, J = 7.4, 7.4 Hz, 1H, Ar), 8.25 (d, J = 8.0 Hz, 1H, Ar); ¹³C NMR (125 MHz, CD₃OD, 60 °C) δ 110.9, 111.6, 111.9 (d, J = 25.2 Hz), 116.3, 117.5, 120.4, 120.8 (d, J = 22.8 Hz), 122.7, 123.7, 124.4, 125.7, 126.6 (d, J = 8.4 Hz), 127.6 (d, J = 8.4 Hz), 127.8, 129.0, 129.1, 129.2, 131.0, 131.2, 134.4, 135.2, 136.9, 137.0, 149.7, 164.5 (d, J = 250.7 Hz); HRMS (FAB) calcd for C₂₅H₁₄FN₂ (MH⁺): 361.1141; found: 361.1141.

4.4.8. *8-Methyldibenzo[1,2:7,8]quinolizino[3,4,5,6-*kla*]perimidine (4h) hydrochloride (Table 5, entry 7).* By a procedure identical with that described for the preparation of **4b**, **3h** (30 mg, 0.068 mmol) was converted into **4h** (15 mg, 62%) by the reaction with Pd(OAc)₂ (1.5 mg, 0.007 mmol), PPh₃ (4.5 mg, 0.017 mmol), and K₃PO₄ (29.0 mg, 0.14 mmol) as red crystals. The crystals were dissolved in CHCl₃, and 4N solution of HCl in dioxane was added to the mixture. After hexane was added to the mixture, the precipitates were collected by filtration to give **4h**·HCl as a brown solid: mp 165–166 °C; ¹H NMR (500 MHz, CD₃OD, 60 °C) δ 2.22 (s, 3H, Ar), 6.79 (d, J = 7.4 Hz, 1H, Ar), 6.89 (d, J = 8.0 Hz, 1H, Ar), 7.00-7.04 (m, 2H, Ar), 7.09 (d, J = 8.6 Hz, 1H, Ar), 7.50-7.53 (m, 2H, Ar), 7.59-7.63 (m, 3H, Ar), 7.74-7.80 (m, 2H, Ar), 8.25 (d, J = 8.6 Hz, 1H, Ar); ¹³C NMR (125 MHz, CD₃OD, 60 °C) δ 21.6, 110.4, 110.9, 116.7, 117.3, 120.5, 122.7, 123.6, 123.8, 125.2, 125.5, 125.7, 127.9, 128.9, 129.1, 130.8, 131.0, 133.9 (2C), 134.3, 135.2, 135.5, 136.9, 137.5, 142.0, 149.7; HRMS (FAB) calcd for C₂₆H₁₇N₂ (MH⁺): 357.1392; found: 357.1390.

Acknowledgments

This work was supported by a Grant-in-Aid for Scientific Research on Innovative Areas ‘Integrated Organic Synthesis’ (H.O.) and Targeted Proteins Research Program from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

References and notes

- Ahmed, E.; Earmme, T.; Ren, G.; Jenekhe, S. A. *Chem. Mater.* **2010**, *22*, 5786–5796.
- Laali, K. K. *Chem. Rev.* **1996**, *96*, 1873–1906.
- Scott, L. T.; Bronstein, H. E.; Preda, D. V.; Ansems, R. B. M.; Bratcher, M. S.; Hagen, S. *Pure Appl. Chem.* **1999**, *71*, 209–219.
- Echavarren, A. M.; Gómez-Lor, B.; González, J. J.; de Frutos, Ó. *Synlett* **2003**, 585–597.
- Pascual, S.; de Mendoza P.; Echavarren, A. M. *Org. Biomol. Chem.* **2007**, *5*, 2727–2734.
- For perimidine derivatives, see: Wu, Z.-A. G.; Haubrich, J. E.; Wang, X.; Liang, R.-C. Patent WO 2004010206.

7. Herbert, J. M.; Woodgate, P. D.; Denny, W. A. *J. Med. Chem.* **1987**, *30*, 2081–2086.
8. Houlihan, W. J.; Cheon, S. H.; Parrino, V. A.; Handley, D. A.; Larson, D. A. *J. Med. Chem.* **1993**, *36*, 3098–3102.
9. Scholz, D.; Schmidt, H.; Prieschl, E. E.; Csonga, R.; Scheirer, W.; Weber, V.; Lembachner, A.; Seidl, G.; Werner, G.; Mayer, P.; Baumruker, T. *J. Med. Chem.* **1998**, *41*, 1050–1059.
10. Ohta, Y.; Kubota, Y.; Watabe, T.; Chiba, H.; Oishi, S.; Fujii, N.; Ohno, H. *J. Org. Chem.* **2009**, *74*, 6299–6302.
11. See also: Ohta, Y.; Oishi, S.; Fujii, N.; Ohno, H. *Chem. Commun.* **2008**, 835–837.
12. Ames, D. E.; Bull, D. *Tetrahedron* **1982**, *38*, 383–387.
13. Ames, D. E.; Opalko, A. *Tetrahedron* **1984**, *40*, 1919–1925.
14. Zhang, M. *Adv. Synth. Catal.* **2009**, *351*, 2243–2270.
15. Thansandote, P.; Lautens, M. *Chem. Eur. J.* **2009**, *15*, 5874–5883.
16. For our recent work on C-H arylation, see: Ohno, H.; Miyamura, K.; Takeoka, Y.; Tanaka, T. *Angew. Chem., Int. Ed.* **2003**, *42*, 2647–2650.
17. Ohno, H.; Yamamoto, M.; Iuchi, M.; Tanaka, T. *Angew. Chem., Int. Ed.* **2005**, *44*, 5103–5106.
18. Ohno, H.; Miyamura, K.; Mizutani, T.; Kadoh, Y.; Takeoka, Y.; Hamaguchi, H.; Tanaka, T. *Chem. Eur. J.* **2005**, *11*, 3728–3741.
19. Watanabe, T.; Oishi, S.; Fujii, N.; Ohno, H. *Org. Lett.* **2007**, *9*, 4821–4824.
20. Ohno, H.; Iuchi, M.; Fujii, N.; Tanaka, T. *Org. Lett.* **2007**, *9*, 4813–4815.
21. Watanabe, T.; Oishi, S.; Fujii, N.; Ohno, H. *Org. Lett.* **2008**, *10*, 1759–1762.
22. Dyker, G.; Stirner, W.; Henkel, G. *Eur. J. Org. Chem.* **2000**, 1433–1441.
23. Recently, a highly related copper-catalyzed halocyclization reaction was reported: Ouyang, H.-C.; Tang, R.-Y.; Zhong, P.; Zhang, X.-G.; Li, J.-H. *J. Org. Chem.* **2011**, *76*, 223–228.
24. Okamoto, N.; Sakurai, K.; Ishikura, M.; Takeda, K.; Yanada, R. *Tetrahedron Lett.* **2009**, *50*, 4167–4169.
25. Patil, N. T.; Mutyala, A. K.; Lakshmi, P. G. V. V.; Raju, P. V. K.; Sridhar, B. *Eur. J. Org. Chem.* **2010**, 1999–2007.
26. For a related synthesis of fused perimidines by annulation of 1-iminoisocoumarin derivatives with 1,8-diaminonaphthalene, see: Dedy, L. W.; Rodemann, T. *J. Heterocyclic Chem.* **1998**, *35*, 1417–1419.
27. Bridges, A. J.; Lee, A.; Maduakor, E. C.; Schwartz, C. E. *Tetrahedron Lett.* **1992**, *33*, 7499–7502.